GSPE interferes with tau aggregation in vivo: Implication for treating tauopathy

Neurobiology of Aging

Volumn 33, Issue 9, 2012, Pages 2072-2081

  Santa Maria, Ismael ^a,b   Diaz Ruiz, Carmen ^a   Ksiezak Reding, Hanna ^a,c   Chen, Alice ^a,c   Ho, Lap ^a,c   Wang, Jun ^a   Pasinetti, Giulio Maria ^a,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Unidad de Investigacion Proyecto Alzheimer   (Spain)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

GSPE; Hyperphosphorylation; JNPL3 mouse model; Tauopathy

Indexed keywords

DRINKING WATER; GRAPE SEED EXTRACT; POLYPHENOL DERIVATIVE; TAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG RESPONSE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOTONEURON; MOUSE; NEUROFILAMENT; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TAUOPATHY; TRANSGENIC MOUSE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; BRAIN; DISEASE MODELS, ANIMAL; GRAPE SEED EXTRACT; HUMANS; LEUCINE; MALE; MICE; MICE, TRANSGENIC; MOLECULAR WEIGHT; MUTATION; POLYPHENOLS; PROLINE; PSYCHOMOTOR PERFORMANCE; SPINAL CORD; TAU PROTEINS; TAUOPATHIES;

EID: 84863474934     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.09.027     Document Type: Article

References (36)

1. Alonso A.C., Zaidi T., Grundke-Iqbal I., Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:5562-5566.
2. Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci 2007, 8:663-672.
3. Brunden K.R., Ballatore C., Crowe A., Smith A.B., Lee V.M., Trojanowski J.Q. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp. Neurol 2010, 223:304-310.
4. Brunden K.R., Trojanowski J.Q., Lee V.M. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat. Rev. Drug Discov 2009, 8:783-793.
5. Bulic B., Pickhardt M., Mandelkow E.M., Mandelkow E. Tau protein and tau aggregation inhibitors. Neuropharmacology 2010, 59:276-289.
6. Chirita C., Necula M., Kuret J. Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 2004, 43:2879-2887.
7. Congdon E.E., Kim S., Bonchak J., Songrug T., Matzavinos A., Kuret J. Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants. J. Biol. Chem 2008, 283:13806-13816.
8. Crowe A., Huang W., Ballatore C., Johnson R.L., Hogan A.M., Huang R., Wichterman J., McCoy J., Huryn D., Auld D.S., Smith A.B., Inglese J., Trojanowski J.Q., Austin C.P., Brunden K.R., Lee V.M. Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 2009, 48:7732-7745.
9. Dickson D.W. Neuropathology of non-Alzheimer degenerative disorders. Int. Clin. Exp. Pathol 2009, 3:1-23.
10. Drubin D.G., Feinstein S.C., Shooter E.M., Kirschner M.W. Nerve growth factor-induced neurite outgrowth in PC12 cells involves the coordinate induction of microtubule assembly and assembly-promoting factors. J. Cell Biol 1985, 101:1799-1807.
11. Hanger D.P. Tau phosphorylation sites http://cnr.iop.kcl.ac.uk/hangerlab/tautable.
12. Hanger D.P., Betts J.C., Loviny T.L., Blackstock W.P., Anderton B.H. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem 1998, 71:2465-2476.
13. Hernández F., Avila J. Tauopathies. Cell. Mol. Life Sci 2007, 64:2219-2233.
14. Ho L., Yemul S., Wang J., Pasinetti G.M. Grape seed polyphenolic extract as a potential novel therapeutic agent in tauopathies. J. Alzheimers Dis 2009, 16:433-439.
15. Karl T., Pabst R., von Hörsten S. Behavioral phenotyping of mice in pharmacological and toxicological research. Exp. Toxicol. Pathol 2003, 55:69-83.
16. Ksiezak-Reding H., Ho L., Santa-Maria I., Diaz-Ruiz C., Wang J., Pasinetti G.M. Ultrastructural alterations of Alzheimer's disease paired helical filaments by grape seed-derived polyphenols. Neurobiol. Aging 2010, 10.1016/j.neurobiolaging.2010.11.006.
17. Le Corre S., Klafki H.W., Plesnila N., Hübinger G., Obermeier A., Sahagún H., Monse B., Seneci P., Lewis J., Eriksen J., Zehr C., Yue M., McGowan E., Dickson D.W., Hutton M., Roder H.M. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:9673-9678.
18. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci 2001, 24:1121-1159.
19. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet 2000, 25:402-405.
20. Li W., Sperry J.B., Crowe A., Trojanowski J.Q., Smith A.B., Lee V.M. Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau. J. Neurochem 2009, 110:1339-1351.
21. Lin W.L., Lewis J., Yen S.H., Hutton M., Dickson D.W. Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau. J. Neurocytol 2003, 32:1091-1105.
22. Lin W.L., Zehr C., Lewis J., Hutton M., Yen S.H., Dickson D.W. Progressive white matter pathology in the spinal cord of transgenic mice expressing mutant (P301L) human tau. J. Neurocytol 2005, 34:397-410.
23. Mazanetz M.P., Fischer P.M. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat. Rev. Drug Discov 2007, 6:464-479.
24. Pérez M., Hernández F., Lim F., Díaz-Nido J., Avila J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J. Alzheimers Dis 2003, 5:301-308.
25. Radde R., Duma C., Goedert M., Jucker M. The value of incomplete mouse models of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:S70-S74.
26. Reynolds C.H., Betts J.C., Blackstock W.P., Nebreda A.R., Anderton B.H. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J. Neurochem 2000, 74:1587-1595.
27. Sahara N., Lewis J., DeTure M., McGowan E., Dickson D.W., Hutton M., Yen S.H. Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. J. Neurochem 2002, 83:1498-1508.
28. Shi J., Yu J., Pohorly J.E., Kakuda Y. Polyphenolics in grape seeds-biochemistry and functionality. J. Med. Food 2003, 6:291-299.
29. Takahashi M., Weidenheim K.M., Dickson D.W., Ksiezak-Reding H. Morphological and biochemical correlations of abnormal tau filaments in progressive supranuclear palsy. J. Neuropathol. Exp. Neurol 2002, 61:33-45.
30. Taniguchi S., Suzuki N., Masuda M., Hisanaga S., Iwatsubo T., Goedert M., Hasegawa M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem 2005, 280:7614-7623.
31. Wang J., Ho L., Zhao W., Ono K., Rosensweig C., Chen L., Humala N., Teplow D.B., Pasinetti G.M. Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J. Neurosci 2008, 28:6388-6392.
32. Wang J., Santa-Maria I., Ho L., Ksiezak-Reding H., Ono K., Teplow D.B., Pasinetti G.M. Grape Derived Polyphenols Attenuate Tau Neuropathology in a Mouse Model of Alzheimer's Disease. J. Alzheimers Dis 2010, 22:653-661.
33. Winklhofer K.F., Tatzelt J., Haass C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J 2008, 27:336-349.
34. Wischik C.M., Edwards P.C., Lai R.Y., Roth M., Harrington C.R. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:11213-11218.
35. Xu J., Sato S., Okuyama S., Swan R.J., Jacobsen M.T., Strunk E., Ikezu T. Tau-tubulin kinase 1 enhances prefibrillar tau aggregation and motor neuron degeneration in P301L FTDP-17 tau-mutant mice. FASEB J 2010, 24:2904-2915.
36. Yadav M., Jain S., Bhardwaj A., Nagpal R., Puniya M., Tomar R., Singh V., Parkash O., Prasad G.B., Marotta F., Yadav H. Biological and medicinal properties of grapes and their bioactive constituents: an update. J. Med. Food 2009, 12:473-484.